Sugi Predict

Sugi Predict / Compounds / SCHEMBL585657

SCHEMBL585657

SCHEMBL585657

CN(C)CCOc1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ HRH3 Q9Y5N1 3/20 0.50
▸ LTA4H P09960 2/20 0.49
▸ KEAP1 Q14145 1/20 0.49
▸ NFE2L2 Q16236 1/20 0.49
▸ LPL P06858 4/20 0.45
▸ LIPG Q9Y5X9 4/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ DGAT1 O75907 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722167 0.92 KDM4E (0.54) CA1CA2CA9HRH3LPL
SCHEMBL25789192 0.89 HRH3 (0.43) CA1CA2CA9HRH3LTA4H
SCHEMBL427591 0.87 CA1 (0.56) CA1CA2CA9LPLLIPG
SCHEMBL628548 0.86 HRH3 (0.62) CA1CA2CA9HRH3
SCHEMBL1129251 0.85 EBP (0.50) CA1CA2CA9HRH3LTA4H
SCHEMBL25405585 0.83 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL430495 0.83 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL428836 0.83 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL428838 0.83 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL16468543 0.83 CA1 (0.48) CA1CA2CA9LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
EP-4633734-A1 COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING Wavebreak Therapeutics, LLC (US) 2025-10-22 — — EP disclosed
US-20250179032-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-06-05 — — US disclosed
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2025-05-01 — — US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
EP-4460496-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE Horizon Therapeutics Ireland DAC (IE) 2024-11-13 — — EP disclosed
EP-4444714-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) 2024-10-16 — — EP disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
WO-2009150381-A2 AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME SANOFI-AVENTIS (FR) 2009-12-17 — — WO disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 — — WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 — — US disclosed
US-7358250-B2 Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity AMGEN INC. (US) 2008-04-15 — — US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 — — EP disclosed
EP-1768982-A2 PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY Amgen Inc. (US) 2007-04-04 — — EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 — — WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 — — US disclosed
US-20060040965-A1 Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity AMGEN INC. 2006-02-23 — — US disclosed
WO-2006004703-A2 PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY AMGEN INC. (US) 2006-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 CA1 419/4885CA2 1205/4885CA9 2221/4885
US-20060040965-A1 Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity LCK, ADCK1, DCK CA1 3116/4885CA2 2230/4885CA9 3744/4885
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK CA1 4831/4885CA2 4610/4885CA9 4732/4885
US-20250179032-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE SLC2A9, SLC2A1, SLC2A8 CA1 3286/4885CA2 1142/4885CA9 118/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK CA1 4831/4885CA2 4610/4885CA9 4732/4885
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 CA1 4495/4885CA2 2438/4885CA9 1272/4885
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIK3CA, PIK3CD, PIK3CB CA1 1036/4885CA2 1554/4885CA9 604/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK CA1 4831/4885CA2 4610/4885CA9 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.